[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.89.187. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1989

Controlled Study of Haloperidol, Pimozide, and Placebo for the Treatment of Gilles de la Tourette's Syndrome

Author Affiliations

From the Tourette and Tic Laboratory and Clinic, New York (Drs E. Shapiro and A. Shapiro); and the Departments of Psychiatry (Drs E. Shapiro, A. Shapiro, and Fulop and Ms Nordlie), Biomathematical Sciences (Drs Hubbard and Mandeli), and Medicine (Dr Phillips), Mount Sinai School of Medicine, New York.

Arch Gen Psychiatry. 1989;46(8):722-730. doi:10.1001/archpsyc.1989.01810080052006
Abstract

• The results of this controlled study of the treatment of 57 patients with Gilles de la Tourette's syndrome suggested that both haloperidol and pimozide were more effective than placebo, but that haloperidol was slightly more effective than pimozide. Adverse effects occurred more frequently with haloperidol vs placebo than with pimozide vs placebo, but the frequency was not significantly different for haloperidol compared with pimozide. Clinically significant cardiac effects did not occur at a maximum dosage of 0.3 mg/kg or 20 mg/d for pimozide and 10 mg/d for haloperidol. However, the QTc interval was prolonged during pimozide treatment compared with that during haloperidol treatment, although the values for both medications were not in an abnormal range.

×